

**BANKA BIOLOO LIMITED**

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016

+91 8688825013 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

An ISO 9001-2015-14001-2015-45001-2018 Company

BBL/ SECT/23/2026-27

Date: 13 August 2026

To,
The Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

NSE Symbol: BANKA

Sub: Investor Presentation on the financial results for the quarter year ended 30 June 2026

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation on the financial results for the quarter ended 30 June 2026.

We request you to kindly take note of the same in your record.

Thank you,

For Banka BioLoo Limited

Vishal Murarka
CEO & Executive Director

Encl: As above



Investor Presentation

Quarter 1, FY 2026–27

Safe Harbour: This presentation contains forward-looking statements subject to risks and uncertainties; actual results may differ materially. It does not constitute an offer or invitation to purchase securities.

Safe Harbour

Disclaimer — forward-looking statements and permitted use of this presentation

- This presentation and the accompanying slides (the “Presentation”), prepared by Banka Bioloo Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis of or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
- This Presentation has been prepared based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of its contents.
- This Presentation may not be all-inclusive and may not contain all information you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. It contains certain forward-looking statements concerning the Company’s future business prospects and profitability, which are subject to several risks and uncertainties; actual results could materially differ. These risks include, but are not limited to, fluctuations in earnings, ability to manage growth, competition (domestic and international), economic growth in India and abroad, ability to attract and retain skilled professionals, time and cost overruns on contracts, management of international operations, government policies, regulations, and interest and fiscal costs prevailing in the economy.
- The Company does not undertake to announce, in case any of these forward-looking statements become materially incorrect in future, or to update any forward-looking statements made from time to time by or on behalf of the Company.


The Wastewater & Sanitation Crisis

The opportunity — scale of the sanitation and water-reuse gap Banka Bioloos addresses

3 Billion

people worldwide face inadequate sanitation and declining water quality.

A \$Bn market gap



Untreated wastewater

The majority of sewage in fast-urbanising cities is discharged without treatment, polluting rivers and groundwater.



Sanitation deficit

Millions still lack access to safe, dignified toilets — an acute burden on marginalised communities.



Water stress & reuse gap

Freshwater scarcity is rising yet recycle-and-reuse infrastructure remains under-built across urban India.

Impact at a Glance

Scale and reach across sanitation, water treatment and railway operations

25,000+

Bio-toilet units deployed

25,000+

Railways systems serviced daily

>12 MLD

Faecal sludge treated

>4 BLD

Used water treated

650+

Employees on roll

7 zones · 26 states

Pan-India presence

Our impact. We address socio-economic inequalities and improve quality of life for marginalised communities through safe sanitation, water reuse and dignified livelihoods.

Partial Client List

Trusted by railways, government bodies, Grade-A developers and industrial clients across India



Business Overview

Banka BioLoo Limited delivers innovation in water, sanitation and hygiene (WaSH) through two focused business lines.

Banka Rail

- AMOC — bio-toilet operations & maintenance
- POH — periodic overhauling & bogie upgradation
- QWS — quick watering systems
- Coach upgradation & passenger amenity works

Multiple Railway zones | 25,000+ systems serviced daily

Banka WaSH

- EPC in urban water & wastewater
- O&M / BOOT for recycle & reuse projects (
- Bio-digesters (DRDO partnership)
- Faecal Septage Treatment Plants (FSTP)

40+ projects under operation | >12 MLD fecal sludge treated | >4+ Billion sewage treated annually (under BOOT projects)

Figures shown are as last reported for Q1 FY25-26 — confirm and update if changed for Q1 FY26-27.

Delivered through:

EPC

O&M

BOOT

HAM

Key Audiences:


Residential and Retail

Government and Railways

Industries and Corporates

Order Book & Outlook

Order booking and unexecuted order book by segment — Q1 FY26-27 actual (₹ Cr)



Notable Wins

- Won an order with Auro Infra - Hyderabad
- We expanded into Bangalore and Mumbai, winning projects with Brigade, Reliance and RMZ.
- We secured multiple projects for our bio-toilets from construction clients and Grade-A developers in Hyderabad.


Execution Outlook

- **Revenue:** Q1 FY26-27 revenue reflects a positive order conversion at the start of the year.
- **Order book:** Q1 booking of ₹4.2 Cr against 16.2 Cr executed leaves an unexecuted book of ₹82 Cr — multi-quarter visibility to rebuild revenue through FY26-27.

Financial Performance

Quarter 1, FY 2026–27 — Standalone, figures in ₹ Lakhs unless noted

Revenue, EBITDA & PAT — Q1 FY25-26 vs Q1 FY26-27 (₹ Lakhs)



REVENUE

1640 ₹ L

20.5%+ YoY vs 1,361 L

EBITDA

151 ₹ L

46.6%+ YoY vs 103 L

PAT

37 ₹ L


162.3%+ YoY vs 14 L

Summary: [One-line takeaway on Q1 FY26-27 performance vs Q1 FY25-26 — fill in once actuals are available.]

Megaliter Varunaa: Scaling a Long-Term Water Infrastructure Portfolio

Portfolio has compounded rapidly across projects, treatment capacity and long-term contracted value

Megaliter Growth — Cumulative Plants, Treatment Capacity & Net LTV (2022–2026)



PROJECTS ONBOARDED
15 (+1 LOI stage)

TREATMENT CAPACITY
11.7 MLD

NET LTV
₹122 Cr

From the first 600 KLD project in mid-2022 to an 11.7 MLD treatment portfolio across 15 projects in mid-2026 (~3 years).

How Megaliter will drive growth in the long-term

- Consolidated financials includes revenue from the subsidiary Megaliter Varunaa Pvt limited as per Ind As 110.
- Life Time Value (LTV) of Megaliter Varunaa Private Limited is ₹122 Cr, has significant long-term growth potential supported by its contracted project portfolio.
- Revenue from the existing contracts is expected to be progressively recognized over the 7–10-year contract tenure, providing sustained revenue visibility.
- The current financials represent the early stage of this long-term revenue recognition cycle.
- As the project portfolio continues to scale, the Company is positioned for stronger revenue and profitability in the coming years.
- The focus remains on the underlying contracted business, future revenue visibility and long-term value creation.

Thank You

WEBSITE

www.bankabio.com

CONTACT PERSON

Ms. Manjula · cs@bankabio.com

PHONE

+91 7780301502 | +91 8688825013

CORPORATE OFFICE

5th Floor, Prestige Phoenix, Begumpet, Hyderabad – 500016

Safe Harbour: This presentation contains forward-looking statements subject to risks and uncertainties; actual results may differ materially. It does not constitute an offer or invitation to purchase securities.